A Best-in-Class Beat-and-Raise the Market Sold: Record Revenue and Reaccelerating IQOS/ZYN Meet a Priced-for-Perfection Tape — Initiating at Hold
Key Takeaways
- Q2 was operationally excellent and the stock still fell 8.4%. Net revenues crossed $10 billion for the first time ($10,140M, +7.1% reported, +6.8% organic), adjusted OI grew 14.9% organically to a 41.9% margin (+330bp), and adjusted diluted EPS of $1.91 (+20.1%) beat the $1.85 consensus by 3.2%. The problem was the top line: revenue landed roughly $115M below the ~$10.26B Street mark, and after a +50% year-to-date run the tape was priced for a clean beat on every line.
- The smoke-free inflection is real and accelerating. The smoke-free business reached 41% of net revenues (+2.9pp) and over 42% of gross profit; IQOS heated-tobacco adjusted in-market sales reaccelerated to +11.4% as the European flavor-ban overhang cleared, and ZYN U.S. offtake snapped back to +26% in the quarter and +36% in June once availability normalized. This is a nicotine platform compounding in the low-teens, not a melting combustibles ice cube.
- ZYN shipments are the swing factor and the source of the sell-off. Q2 can shipments (119M in the U.S.) reflected the tail of an H1 restock that came in ~10–20M cans below management's own assumption, management flagged a possible Q3 volume "adjustment," and the full-year 800–840M can guide now looks weighted toward the low end. Underlying offtake is strong; reported shipments will stay noisy for another quarter or two.
- The guidance raise was genuine but lower-quality than the headline. FY25 adjusted EPS was lifted to $7.43–$7.56, but part of the increase came from a better tax rate and currency, and the FX benefit itself landed ~4 cents below consensus on Swiss-franc transactional losses. H2 also carries pre-flagged phasing headwinds: a ~1bn-stick Q1 IQOS shipment timing benefit reverses in Q4, device-sale easy comps do not repeat, and combustible volumes step down to -3–4%.
- Rating: Initiating at Hold. Philip Morris is running the best consumer-staples transformation in the market, and we would own it at the right price. At ~22x forward earnings after a +50% YTD advance, with the stock itself signaling crowded positioning by dropping 8.4% on a beat-and-raise, the 12-month risk/reward is balanced rather than asymmetric. We initiate at Hold and would upgrade on a valuation reset or on confirmation that ZYN offtake sustains mid-30s% and IQOS holds double-digit IMS through H2.
Results vs. Consensus
Q2 2025 Scorecard
| Metric | Q2 2025 Actual | Consensus | Beat/Miss | Magnitude |
|---|---|---|---|---|
| Net Revenues | $10,140M | ~$10,255M (Zacks) | Miss | -$115M (-1.1%) |
| Organic Net Revenue Growth | +6.8% | ~+7–8% | In line / soft | ~+8% ex-Indonesia technical |
| Adjusted Diluted EPS | $1.91 | $1.85 | Beat | +$0.06 (+3.2%) |
| Reported Diluted EPS | $1.95 | n/a | +26.6% YoY | n/a |
| Adjusted OI | $4,246M | ~$4,150M (implied) | Beat | +16.1% reported / +14.9% organic |
| Adjusted OI Margin | 41.9% | ~41% (implied) | Beat | +330bp YoY (+300bp organic) |
| Total Shipment Volume | 200.1B units | n/a | +1.2% | SFP +11.8%, cigarettes -1.5% |
| FY25 Adj. EPS Guide (midpoint) | $7.50 | ~$7.49 | Raised | from prior; +13–15% reported |
Year-Over-Year Comparisons
| Metric | Q2 2025 | Q2 2024 | YoY Change |
|---|---|---|---|
| Net Revenues | $10,140M | $9,468M | +7.1% (+6.8% organic) |
| Gross Profit | $6.9B | ~$6.15B | +12.1% (+11.2% organic) |
| Adjusted OI | $4,246M | ~$3,657M | +16.1% (+14.9% organic) |
| Adjusted OI Margin | 41.9% | 38.6% | +330bp |
| Adjusted Diluted EPS | $1.91 | $1.59 | +20.1% (+18.9% ex-FX) |
| Reported Diluted EPS | $1.95 | $1.54 | +26.6% |
| Smoke-Free % of Net Revenue | 41% | ~38% | +2.9pp |
| HTU Adjusted IMS Growth | +11.4% | n/a | Reaccelerated to double digit |
Quality of Beat/Miss
Revenue: The $115M miss is the entire story of the day, and it is worth being precise about what caused it. Organic growth of +6.8% (roughly +8% excluding a known Indonesia commercial-model technical impact) is squarely inside the full-year 6–8% frame: this was not a demand air-pocket. The shortfall was concentrated in two lines: ZYN can shipments, where the H1 restocking benefit came in below plan and pulled reported shipments below the offtake trend, and cigarettes, where volume turned negative (-1.5%) on Turkey supply-chain disruption and Indonesian illicit-trade pressure. Both are timing/optics issues rather than franchise problems, but both sit on the revenue line the Street models most closely.
Margins: The cleanest part of the print. Adjusted OI margin of 41.9% expanded 330bp year-over-year (300bp organic), and Q2 organic OI-margin expansion of ~300bp actually accelerated versus Q1's ~200bp. The driver is structural: smoke-free gross margin now runs above 70%, roughly 4.5 points above combustibles at the current mix, so every point of revenue shift toward IQOS and ZYN is margin-accretive. Layered on top are ~$500M of H1 gross cost savings (the company is now $1.2B into a $2B 2024–2026 program) and combustible pricing of +7.2%. This is high-quality, repeatable margin expansion.
EPS: Adjusted EPS of $1.91 grew 20.1%, but the composition matters for how the market read it. Currency added only ~2 cents (four cents below the guided/consensus assumption) because Swiss-franc volatility late in the quarter generated intercompany transactional losses against PMI's heavy Swiss cost base. So the operational EPS beat was strong on its own, but the FX line that investors expected to amplify it instead subtracted from it: a nuance that made the raise feel lower-quality than the +20% headline suggests.
Segment Performance
Category Mix: Q2 2025
| Category | Net Revenue | Reported Growth | Organic Growth | Gross Profit Growth | Notable |
|---|---|---|---|---|---|
| Smoke-Free Business | $4.2B | +15.2% | +14.5% | +23.3% (+21.5% org) | 41% of revenue; >70% gross margin |
| — IQOS (inhalable/HTU) | >$3.0B | Double digit | n/a | n/a | 76% global heat-not-burn volume share |
| — Oral (ZYN/pouches) | incl. above | Cans +26.5% | n/a | n/a | U.S. pouches +40% to 190M cans |
| — E-vapor (VEEV) | incl. above | Volume +100% | n/a | n/a | #1 closed-pod in 6 EU markets |
| Combustibles | $6.0B | +2.1% | +2.0% | +5.0% (+4.8% org) | Marlboro at post-spin share high 10.7% |
| Total PMI | $10.1B | +7.1% | +6.8% | +12.1% | Record quarterly net revenue |
Regional Net Revenue & Adjusted OI Margin: Q2 2025
| Region | Net Revenue | Reported / Organic Growth | Adj. OI Margin | Margin Δ YoY |
|---|---|---|---|---|
| Europe | $4,234M | +8.7% / +7.3% | 47.2% | +4.3pp |
| SSEA, CIS & MEA | $2,926M | +5.6% / +4.9% | 34.3% | +2.0pp |
| East Asia, Australia & GTR | $1,708M | +2.1% / +1.6% | 49.9% | +4.9pp |
| Americas | $1,272M | +12.7% / +17.0% | 30.6% | +0.9pp |
| Total PMI | $10,140M | +7.1% / +6.8% | 41.9% | +3.3pp |
Smoke-Free / IQOS: The Reacceleration
IQOS is the core of the entire investment case, and Q2 was the quarter the European overhang lifted. Heated-tobacco-unit adjusted in-market sales growth reaccelerated to +11.4% globally, back into the double digits management targets (10–12% for the year), driven by Europe, where adjusted IMS grew +9.1% and adjusted market share rose 1.2pp to 10.9%. The single most important callout is Italy, Europe's largest IQOS market by volume, which reaccelerated as the transitory disruption from the EU characterizing-flavor ban washed through. Japan added another robust quarter (+7.8% adjusted IMS against a tough ILUMA-launch comparison, HTU share +2.3pp to 31.7%, crossing 10 million users), and the newer growth markets (Indonesia, the Gulf, Mexico, the Philippines, global travel retail) are building momentum. IQOS crossed $3 billion in quarterly net revenues and holds ~76% of the global heat-not-burn category by volume.
"I'm especially pleased to confirm the acceleration in IQOS HTU adjusted in-market sales growth to plus 11.4% in Q2, notably driven by Europe, and including excellent progress in its largest market of Italy as the impact of the characterizing flavor ban recedes." — Emmanuel Babeau, CFO
Assessment: The flavor-ban clearing is the key de-risking event of the quarter. IQOS growth had decelerated in prior quarters partly on that regulatory disruption in affected European markets; its resolution restores the double-digit trajectory that underpins the smoke-free re-rating. The one honest caveat management pre-flagged: H2 IQOS growth is skewed to Q4 because Q3 laps a strong prior-year comparison, and a ~1bn-stick Q1 shipment timing benefit reverses in Q4. Watch adjusted IMS (the cleaner demand signal) rather than reported HTU shipments through year-end.
ZYN & Oral: Strong Offtake, Noisy Shipments
ZYN is where the quarter was won operationally and lost in the tape. U.S. consumer offtake reaccelerated to +26% for Q2 and +36% in June (Nielsen), and management said the first two weeks of July ran north of +37%, roughly back in line with the ~39% category growth rate: the clearest evidence that the 2024 supply constraint is fully behind the brand and that ZYN has returned to its category-driving position. U.S. pouch volumes grew over 40% to 190M cans; international can volumes rose +65% (+179% ex-Nordics), with ZYN now in 44 markets. The complication is shipments versus offtake: because H1 involved restocking the value chain after last year's out-of-stocks, reported can shipments (119M U.S. cans in Q2, +41% YoY) are a distorted read, and management now estimates the net full-year restocking benefit at ~40M cans, ~10–20M below its earlier assumption.
"We are a bit below our expectation... if I was to give a number, it's probably maybe 10, 20 million cans below. Frankly, I'm not able to give more specific than that. We are talking about a few days of sales, so it's really small. What is really important is the great dynamism ZYN is facing now that there is full availability." — Emmanuel Babeau, CFO
Assessment: The underlying ZYN demand signal is unambiguously strong; the shipment optics are unambiguously noisy. Management flagged a possible Q3 volume "adjustment" as pipeline inventory normalizes, which means the full-year 800–840M can guide is realistically weighted to the low end and Q4 must carry a visible step-up. For a stock priced for perfection, "we shipped fewer cans than the buy-side modeled and Q3 could dip" was the sound bite that mattered, even though offtake (the number that actually predicts the franchise) accelerated.
VEEV / E-Vapor: The Third Leg Turns Profitable
VEEV shipments more than doubled year-over-year, and the strategically important disclosure is margin: management said VEEV gross margin has improved by more than ten percentage points since the start of 2025 and now believes the brand can eventually reach IQOS-like percentage gross margins provided consumer loyalty holds. VEEV holds the #1 closed-pod position in six European markets including Italy and Greece, and the new VEEV inPrime innovation targets a premium experience with better pod economics. This is the completion of the three-category "multi-category under the IQOS umbrella" thesis PMI laid out at its June Europe event.
Assessment: E-vapor was historically PMI's least-favored category on loyalty and margin grounds; the double-digit gross-margin improvement is what changes the calculus. VEEV is still small, but a profitable third leg materially strengthens the "full smoke-free portfolio" argument versus single-category competitors. Not yet a needle-mover on revenue; increasingly a needle-mover on the strategic narrative.
Combustibles: Resilience Funds the Transition
Combustible net revenue grew +2.1% (+2.0% organic) and gross profit +5.0% despite volume turning modestly negative (-1.5%), with Marlboro reaching a post-spin category-share high of 10.7%. Pricing of +7.2% in Q2 (+7.7% H1) is the engine. Management guided combustible volume to -3–4% in H2 (Turkey accounting for roughly half of the decline, plus Indonesian illicit trade) but still expects combustible gross-profit growth for the full year on pricing and efficiencies.
Assessment: This is exactly the model PMI needs combustibles to run: low-single-digit volume decline more than offset by robust pricing, throwing off the cash and gross profit that funds smoke-free investment and the dividend. The Q2 volume dip is largely idiosyncratic (Turkey supply chain, Indonesia illicit) rather than accelerating structural decline. The watch item is whether pricing power holds as volumes step down in H2.
Key Operating KPIs
| KPI | Q2 2025 | Trend | Read |
|---|---|---|---|
| HTU adjusted in-market sales growth | +11.4% | Reaccelerated | Back to double digit; FY target 10–12% |
| IQOS quarterly net revenue | >$3.0B | Record | Core smoke-free engine |
| Global heat-not-burn volume share | ~76% | Stable | Category leadership intact |
| Japan HTU adjusted share | 31.7% | +2.3pp | 10M-user milestone crossed |
| Europe HTU adjusted share | 10.9% | +1.2pp | Flavor-ban overhang clearing |
| ZYN U.S. offtake (Nielsen) | +26% Q2 / +36% June | Reaccelerating | Back to category-driving growth |
| ZYN U.S. shipments | 119M cans (+41%) | Noisy | Restock rolling off; FY guide 800–840M |
| Smoke-free consumers (LAU) | ~41.5M | +~5M YoY | 97 markets, 20 with all three brands |
| Cigarette volume | 155.2B (-1.5%) | Declining | Turkey/Indonesia; FY guide ~-2% |
| Combustible pricing | +7.2% | Robust | FY revised to +6–7% |
Key Topics & Management Commentary
Overall Management Tone: Confident and granular, with a CFO-only call (Emmanuel Babeau presenting alone) that leaned into the operational momentum on IQOS and ZYN while being unusually forthcoming about the H2 phasing headwinds and the ZYN restocking imprecision. Management did not oversell: it repeatedly framed the smoke-free acceleration as the signal and the shipment/currency noise as timing. The posture on ZYN restocking ("let's be a bit humble here") was candid rather than defensive, which is the right tone but also, on a priced-for-perfection stock, an admission that the buy-side's shipment model had gotten ahead of reality.
1. The Revenue Miss That Overshadowed the Beat
The defining tension of the print is that PMI beat on every profit line and raised the guide, yet the shares fell 8.4%. The proximate cause was a ~$115M revenue miss against the ~$10.26B consensus, driven by lighter-than-modeled ZYN shipments and negative cigarette volume. In most tapes a 1% revenue miss paired with a 3% EPS beat and a raise is a non-event; here it was a de-rating catalyst because the stock had appreciated 50% year-to-date and entered the print near its 52-week closing high, leaving no room for a blemish on the highest-visibility growth lines.
Assessment: The miss is low-quality-bearish (timing and mix on two lines) but the reaction is high-quality-informative: it tells you the market has fully embraced the smoke-free story and is now demanding flawless execution to hold a premium multiple. That is precisely the setup that argues for patience on entry rather than chasing.
2. Smoke-Free Crosses 41% of Revenue: the Structural Re-Rating
Smoke-free products reached 41% of total net revenues (+2.9pp YoY) and over 42% of gross profit (+3.8pp), with H1 smoke-free gross margin surpassing 70%: roughly 4.5 points above combustibles at the current mix. This is the mechanical basis for PMI's margin expansion and the reason the equity has re-rated from a cigarette multiple toward a consumer-platform multiple over the past two years.
"Our smoke-free business accounted for 41% of total net revenues and over 42% of total gross profit. This high-quality performance reflects the increasing profitability of our three smoke-free categories: scale, operating leverage, and efficiencies combined." — Emmanuel Babeau, CFO
Assessment: Once smoke-free crosses 50% of both revenue and gross profit (plausibly in 2026) PMI's classification as a "tobacco" stock becomes increasingly hard to defend, and the multiple debate shifts decisively. That mix-shift is the central engine of the bull case, and it is on track. The question the rating turns on is not whether the shift happens but how much of it is already in the price.
3. IQOS IMS Reaccelerates to +11.4% as the Flavor-Ban Overhang Clears
Covered in Segment Performance, but its thesis weight warrants a topic. The reacceleration to +11.4% adjusted IMS is the most important operational fact of the quarter because IQOS is ~two-thirds of the smoke-free revenue base and the anchor for ZYN and VEEV cross-sell. Europe's return to +9.1% IMS with 1.2pp of share gain, led by Italy, confirms the 2024 deceleration was a regulatory-disruption story rather than a demand-saturation story.
Assessment: Thesis-supportive and de-risking. Sequential trends across Germany, Spain, Romania, Greece and Bulgaria are strong, and the new-market cohort (Gulf, Indonesia, Mexico, GTR) provides a multi-year runway beyond the mature Japan/Europe base.
4. ZYN Restocking: Signal vs. Noise
The single most-debated topic in the Q&A. The mechanics: after 2024 out-of-stocks, PMI rebuilt channel inventory in H1 2025 (mostly Q1). The net full-year restocking benefit is now estimated at ~40M cans, ~10–20M below the earlier assumption, and a Q3 destocking "adjustment" is possible as the channel normalizes. Management's counter is that offtake (the true demand signal) accelerated to +26% Q2 / +36% June / +37% early July, and that Q2 sequential offtake growth of ~12% versus Q1 was the biggest sequential jump since Q1 2024.
"We should focus on what is really important, which is the great dynamism that ZYN is facing now that there is full availability... we are going now in line with the market. It just shows that we have absolutely resumed a strong momentum." — Emmanuel Babeau, CFO
Assessment: Management is analytically correct that offtake is the number that matters, and it is excellent. But for a stock where ZYN carries a disproportionate share of the growth premium, the combination of "restock lower than we thought" and "Q3 could dip" reset near-term expectations. This is a demand-quality question that resolves favorably over two to three quarters if offtake holds: and it is the single most important thing to watch into Q3.
5. Margin Expansion: 41.9% Adjusted OI Margin, +330bp
Adjusted OI margin of 41.9% (+330bp reported, +300bp organic) is the highest-quality element of the quarter, and Q2's ~300bp organic expansion actually accelerated versus Q1's ~200bp. Three drivers: smoke-free mix (70%+ gross margin dragging the blend up), the $2B 2024–2026 cost program (now $1.2B delivered, over $500M in H1 alone), and combustible pricing net of inflation. Management raised the FY organic OI growth range to +11–12.5%.
Assessment: This is a durable, multi-year margin story, not a one-quarter print. The mix-driven component compounds mechanically as smoke-free grows share; the cost program is halfway delivered against a hard target. Margin is the least of PMI's worries.
6. The Currency-Quality of the Raise
Management raised FY adjusted EPS to $7.43–$7.56 (+13–15% reported, +11.5–13.5% ex-currency), but the composition drew scrutiny. The FX benefit for the year is estimated at ~10 cents, yet Q2's currency contribution came in ~4 cents below consensus because a sharp late-quarter Swiss-franc move generated intercompany transactional losses against PMI's heavy Swiss cost base, largely offsetting the euro translation tailwind. A slightly better tax rate (22–23%) also helped the raise.
"Versus the 10 cents we're coming up with, we are around 4 cents versus consensus below what the consensus was expecting. It's largely the Swiss franc... the intercompany flows mean that when there is a lot of volatility, that is generating some transactional losses." — Emmanuel Babeau, CFO
Assessment: The operational raise is real, but the market wanted a weaker dollar to amplify EPS and instead got a currency drag on the transactional line. This made the raise feel lower-quality than the +20% EPS headline implies, and it fed the broader "beat, but not the beat we wanted" reaction.
7. H2 Phasing Headwinds Management Pre-Flagged
To its credit, management was explicit that H2 will look softer than H1 for reasons unrelated to franchise health: (1) the ~1bn-stick Q1 IQOS shipment timing benefit reverses in Q4; (2) 2024's device-sale easy comps (ILUMA launch) do not repeat, so smoke-free margin growth decelerates on a YoY basis even as absolute margins stay high; (3) the H1 restocking tailwind is gone; and (4) combustible volume steps down to -3–4%. Total PMI volume could see a modest H2 decline even as the company still targets a fifth consecutive year of full-year volume growth (~+1%).
Assessment: This is responsible guidance, but it also means the easy H1 comparisons that flattered the first half give way to a tougher optical setup in H2. The fundamentals are intact; the reported growth rates will look less spectacular, which for a premium-multiple stock is its own risk.
8. Regulatory: EU TPD Excise Revision and FDA IQOS ILUMA Timing
Two regulatory items surfaced. First, the EU published a proposal to revise the Tobacco Excise Directive; management noted it contains a welcome differentiation between smoke-free and combustible minimum rates but lacks a plan to counter illicit trade (9.2% of EU cigarette consumption in 2024). It stressed this is the start of a multi-year process requiring unanimity (the last revision took ~two years) and declined to quantify. Second, on IQOS ILUMA U.S. authorization, management still hopes for H2 2025 but acknowledged the FDA's heavy workload could push it into 2026.
Assessment: The EU TED is a multi-year overhang to monitor, not a 2025–2026 P&L event, and the smoke-free differentiation in the initial draft is directionally favorable. The FDA ILUMA timing slipping toward 2026 is a mild negative: the U.S. at-scale IQOS launch is a genuine future optionality that keeps getting deferred, though ZYN is carrying the U.S. smoke-free story in the interim.
9. Capital Allocation: Dividend, Deleveraging, No Buybacks
PMI declared a $1.35 quarterly dividend ($5.40 annualized, ~3.3% yield at the post-print price), raised FY operating cash flow guidance to ~$11.5B, and reiterated its target to reach ~2x net debt / adjusted EBITDA by end-2026. Capex was nudged to ~$1.66B (almost entirely smoke-free capacity, including international ZYN). No share repurchases are planned in 2025.
Assessment: Capital allocation is disciplined and deleveraging-first, which is the correct priority given the Swedish Match acquisition debt. The progressive dividend is well-covered by rising cash flow, and buybacks are a 2026+ optionality once leverage hits target. This is a cash-return story with a growth engine attached, and the balance sheet is healing on schedule.
Guidance & Outlook
| Metric | Prior FY25 Guide | New FY25 Guide | Change |
|---|---|---|---|
| Adjusted Diluted EPS | $7.36–$7.49 (approx.) | $7.43–$7.56 | Raised |
| Adj. EPS growth (reported) | +12–14% | +13–15% | Raised |
| Adj. EPS growth (ex-currency) | +11–13% (approx.) | +11.5–13.5% | Raised |
| Organic net revenue growth | +6–8% | +6–8% | Maintained |
| Organic OI growth | +10.5–12.5% (approx.) | +11–12.5% | Raised (floor up) |
| Operating cash flow | ~$11B (approx.) | ~$11.5B | Raised |
| Effective tax rate | ~23% | 22–23% | Improved |
| Q3 2025 Adj. EPS | n/a | $2.08–$2.13 | New (vs. ~$2.10 Street) |
The raise is genuine but modest, and its composition is the story: the higher range reflects the strong H1 operational delivery plus a slightly better tax rate, partly offset by the currency-transaction drag discussed above. Management maintained the +6–8% organic revenue frame (a signal that the revenue "miss" was a consensus-modeling issue on shipments, not a change in the demand outlook) while lifting the OI-growth floor.
Implied H2 shape: The Q3 adjusted EPS guide of $2.08–$2.13 (midpoint $2.105, including ~5 cents of favorable FX) sits roughly in line with the ~$2.10 Street mark, so the near-term bar is set at consensus rather than above it. Management steered HTU shipments to 38.5–39.5B for Q3 and reiterated 10–12% full-year HTU adjusted IMS growth "skewed to Q4," combustible volume of -3–4% in H2, and a ZYN Q4 step-up to land inside the 800–840M can range.
Guidance style: PMI has a multi-year record of setting conservative organic frames and delivering at or above the top; the maintained +6–8% revenue range with a raised OI floor is consistent with that pattern. The nuance for H2 is that the phasing headwinds (Q4 IQOS timing reversal, no device comp, restock gone) make the reported optics choppier even if the underlying trajectory is unchanged.
Analyst Q&A Highlights
Whether the Lower Restock Signals Softer ZYN Demand and How the Q4 Step-Up Math Works
The opening question pressed the read-through of a smaller-than-expected restock: does a lower restocking need imply the market's forward ZYN growth expectations were too high? The questioner also walked the arithmetic: if Q3 shipments are roughly flat to Q2, Q4 needs a large sequential step-up to reach the 800–840M can guide, against a historically shorter-shipping-days Q4. Management separated the restock imprecision (a few days of sales) from the underlying offtake acceleration.
Q: "You're saying restock was less than what you had expected. How should one read it: that your expectations for future growth were higher earlier and now lower?... If Q3 is flat versus Q2, then in Q4 you need 219 to 259 million cans for that 800 to 840 guide range, which would imply almost 15% to 36% growth on a quarter-on-quarter basis."
— Gaurav Jain, Barclays
A: "Let's be a bit humble here... it's probably maybe 10, 20 million cans below. We are talking about a few days of sales, so it's really small. We should focus on what is really important, which is the great dynamism ZYN is facing now that there is full availability. June was growing 36%... the first two weeks of July we are north of 37%. So we have absolutely resumed a strong momentum."
— Emmanuel Babeau, CFO
Assessment: Management engaged the substance rather than deflecting, and its analytical point (offtake, not shipments, predicts the franchise) is correct. But it did not resolve the Q4 step-up math, which requires either a strong offtake continuation or channel refill to hit the guide. That unresolved arithmetic is why the low end of the range is the realistic base case.
FDA Timing for IQOS ILUMA and the Sustainability of the IMS Reacceleration
A two-part question probed the U.S. IQOS ILUMA authorization timeline and the drivers behind the international IMS reacceleration. Management offered no new PMTA news and softened the ILUMA timeline, while attributing the IMS reacceleration to the European flavor-ban recovery plus new-market momentum.
Q: "In terms of IQOS ILUMA U.S. approval timing, are you still sticking to your expectation of a second-half authorization? And can you talk about the drivers of the reacceleration in IMS and its sustainability for the second half?"
— Eric Serrano, Morgan Stanley
A: "I have nothing new to report on the PMTA for IQOS ILUMA. We are still hoping for an approval in H2, but we are acknowledging the FDA's agenda and workload is very heavy, and it is clear we don't have certainty we will get this PMTA in '25... that could move to 2026. On the reacceleration: it's really Europe, where the characterizing-flavor-ban effects are waning, plus new growth markets: global travel retail, Indonesia, the Gulf, Mexico, the Philippines."
— Emmanuel Babeau, CFO
Assessment: The ILUMA timeline slipping toward 2026 is a mild negative for the U.S. optionality but not thesis-altering: ZYN is carrying the U.S. smoke-free story. The IMS reacceleration attribution (flavor-ban recovery plus a broad new-market cohort) is credible and points to sustainability, with the honest caveat that Q3 laps a tough comp.
Composition of the Guidance Raise and the H2 Margin Bridge
A question sought to decompose the raise (how much is stronger operations versus tax and currency) and to understand the H2 phasing and cost dynamics management flagged. The answer laid out the full H2 bridge in unusual detail.
Q: "Is it fair to say the second half is more or less in line with your previous expectations? Can you provide more detail on the considerations in the second half (you called out phasing, comparisons and costs) and the impact on margins and the timing of when those lap into the base?"
— Matt Smith, Stifel
A: "The momentum in Q2 on smoke-free is even better than Q1... we expect a continuation of these very strong momentum in H2. What is going to be less favorable is combustible: almost flat in H1, and we expect 3% to 4% decline in H2. Then you have phasing on smoke-free with nothing to do with performance: the 1 billion stick shipment in Q1 that we compensate in Q4; super-favorable device comps in H1 that don't repeat; and the restocking that benefited H1."
— Emmanuel Babeau, CFO
Assessment: This was the most useful exchange on the call. Management effectively told investors the H2 deceleration is optical (phasing and comps) rather than fundamental, and that smoke-free momentum is unchanged. It also implicitly conceded the raise was partly non-operational, which is the honest framing but not the one a premium multiple wants to hear.
Whether the Low End of the ZYN Shipment Guide Is Now the Realistic Outcome
A direct challenge on the full-year can guide: given the softer restock, is the low end more realistic, and is the high end even achievable? The question folded in a request for a capacity update.
Q: "Based on everything you're seeing, should we assume the lower end of your full-year shipment guidance range is more realistic? I'm trying to understand if the high end is even possible in your mind. And can you update us on capacity and when it will increase?"
— Bonnie Herzog, Goldman Sachs
A: "If we give this bracket, we believe we can finish the year within the bracket at every point... the 10 to 20 million lower restocking is having an impact, but the restart of ZYN can be very powerful: 36%, 37%. So we are still comfortable with the 800 to 840 million can bracket. On capacity, we have built a comfortable capacity to face all kinds of dynamic growth scenarios, so we are comfortable for the coming quarters."
— Emmanuel Babeau, CFO
Assessment: Management defended the full range rather than conceding the low end, but the sub-text (a restock headwind offset by strong-but-uncertain offtake) leaves the low end as the sensible base case. The capacity reassurance is genuinely important: unlike 2024, supply is no longer the constraint, so any shipment shortfall from here is demand/inventory timing, not the company's inability to make cans.
Post-Availability ZYN Strategy: Will PMI Get More Aggressive on Promotion?
A follow-up asked how returning to full availability changes ZYN commercial strategy: specifically whether PMI will lean harder into pricing and promotion to accelerate share now that it can ship to demand.
Q: "Now that you're essentially back in stock and can ship to demand, how does that change your strategy for ZYN as it relates to pricing and promotions? Are you going to get more aggressive in an attempt to grow ZYN faster and take more share?"
— Bonnie Herzog, Goldman Sachs
A: "During many quarters we've been refraining ourselves from acquiring new users because we were not able to supply the need... So we're going to restart normal activity, and that will certainly include more promotion. We have a much lower level of promotion than any other brand, and it will stay like that, but it doesn't mean we cannot increase it. That will be advertising and commercial activity at the point of sale."
— Emmanuel Babeau, CFO
Assessment: The reactivation of the full commercial engine (deliberately throttled during the shortage) is the incremental growth lever for H2 and 2026. It supports the offtake-acceleration case but is also a modest margin/mix consideration if promotion scales. Net positive for the franchise; something to watch in the ZYN gross-margin line.
Why the Expected Currency Tailwind Failed to Materialize
With the dollar weakening through the quarter, an analyst asked why PMI did not capture a larger FX benefit: and how to think about the currency tailwind if the dollar keeps falling.
Q: "Can you provide color on exactly what transpired in the quarter: you didn't get the benefit you'd been guiding for in Q2, despite the dollar weakening further? We would have expected an even bigger benefit to adjusted EPS on a more favorable currency outlook."
— Gerald Pascarelli, Needham
A: "Versus the 10 cents we're coming up with, we are around 4 cents versus consensus below what consensus expected. It's largely the Swiss franc: both the negative impact because we have strong cost exposure to Switzerland, and because intercompany flows generate transactional losses when there is a lot of volatility. The Swiss franc is to a large extent offsetting the benefit we have on the euro."
— Emmanuel Babeau, CFO
Assessment: This crystallized the "quality of the raise" concern. PMI's Swiss cost base makes it structurally exposed to Swiss-franc strength, which can neutralize euro-translation tailwinds. It is a reminder that PMI's reported EPS is more FX-sensitive (and in less predictable directions) than a simple weak-dollar-helps framing suggests.
What They're NOT Saying
- A hard number on underlying (offtake-based) ZYN growth for the year. Management gave offtake data points (+26% Q2, +36% June) but no offtake-based full-year framework, keeping the guide anchored to the shipment can-count that it just admitted it can't forecast precisely. The number that would settle the demand-quality debate is the one not provided.
- Quarterly capex and quarterly free cash flow detail. Management declined to disclose Q2 capex ("we don't split that by quarter") and was vague on the working-capital drag, attributing the weaker H1 cash generation mostly to a German duty payment and a final U.S. tax payment (cumulatively >$1B). For a deleveraging story, more cash-flow transparency would help.
- Updated FX hedge rates. After providing hedge detail last quarter, the CFO explicitly declined to repeat it ("that's not something I intend to do each time"), which reduces visibility precisely as currency became a swing factor in the EPS bridge.
- Any framing of the OBBBA U.S. tax reform impact. Management said it is "still reviewing the implications" of the new U.S. tax law: a deferral that leaves a potential 2026 tax variable unquantified.
- A specific FDA ILUMA decision date or contingency. The U.S. at-scale IQOS launch keeps sliding; management offered hope for H2 2025 but no plan B for a 2026 slip beyond "ZYN is carrying the U.S."
Market Reaction
- Pre-print setup (July 21 close): $180.48, up ~50.0% year-to-date and ~68.3% over the trailing twelve months, sitting near the top of a 52-week closing range of $107.12–$184.95. The stock entered the print priced for a clean beat across every line.
- Reaction session (July 22): Gapped down ~6.0% at the open ($169.62), traded as low as $162.74 intraday, and closed at $165.27, down 8.4% (-$15.21) on the day.
- Volume: 19.8M shares versus a 5.0M 30-day average (4.0x): a heavy, positioning-driven session, not thin-tape noise.
- Market context: The S&P 500 closed essentially flat (+0.1%) on the session, confirming the move was idiosyncratic to PMI rather than a broad risk-off day.
The 8.4% drop on a beat-and-raise is best understood as a positioning reset, not a fundamental repricing. Three elements combined: a ~$115M revenue miss on the two highest-visibility growth lines (ZYN shipments and cigarettes), a currency-quality question that made the raise feel thinner than the +20% EPS headline, and a valuation that had run to ~24x forward on a +50% YTD move, leaving zero tolerance for a blemish. When a defensive-growth compounder trades near record highs, the market demands perfection; PMI delivered an excellent quarter that was merely very good on the lines that mattered most to consensus models, and the stock corrected the premium.
The post-print price of $165.27 is a materially better entry than the $180.48 pre-print level, and it resets the forward multiple to ~22x. That is the constructive read. The cautious read is that the same phasing headwinds management pre-flagged (Q4 IQOS reversal, combustible -3–4%, restock roll-off) will make H2 reported growth look choppier, which can keep a lid on multiple re-expansion even as the business compounds.
Street Perspective
Debate: Is the ZYN Shipment Wobble a Demand Signal or an Inventory Artifact?
Bull view: Offtake (the only number that predicts the franchise) reaccelerated to +26% Q2, +36% June, +37% early July, back in line with a ~39% category. The shipment softness is pure restock roll-off, a few days of channel inventory, and capacity is now unconstrained. Once the pipeline normalizes in Q3, shipments re-converge to offtake and the growth premium is validated.
Bear view: The market had modeled ZYN as a clean beat every quarter; the first sequential shipment decline plus a below-plan restock plus a flagged Q3 "adjustment" shows the buy-side ran ahead of reality. If Q4 requires a 15–36% sequential shipment jump to hit the guide, the low end is the base case and 2026 estimates come down.
Our take: Bull on the franchise, cautious on the near-term optics. Offtake is genuinely strong and capacity is no longer the bottleneck, so the demand case is intact. But we would not underwrite the high end of the can guide, and we expect one more quarter of noisy shipment prints before the signal-to-noise improves. This resolves favorably by year-end if June/July offtake holds.
Debate: Has PMI Re-Rated to a Consumer-Platform Multiple, or Is It Still a Tobacco Stock?
Bull view: Smoke-free is 41% of revenue and 42% of gross profit, compounding 15%+ at 70%+ gross margin; once it crosses 50% (plausibly 2026) the "tobacco" label is indefensible and PMI deserves a premium staples multiple. Low-double-digit EPS growth plus a ~3.3% yield is a rare CPG algorithm, and 22x is cheap for it.
Bear view: The re-rating has already happened: PMI moved from a mid-teens tobacco multiple to low-20s over two years, and the +50% YTD run pulled forward much of the mix-shift optionality. ESG mandates cap the buyer base regardless of category mix, and regulatory tail risk (EU TED, FDA, flavor bans) never disappears for a nicotine company.
Our take: The re-rating is real and, in our view, largely justified by the mix shift: but it is also largely done. At 22x the market is already paying for a consumer-platform compounder, which means the incremental return comes from earnings delivery, not further multiple expansion. That is a solid Hold algorithm, not an asymmetric Outperform one, at this price.
Debate: Does the H2 Phasing Deceleration Matter?
Bull view: The H2 softness is entirely optical (the Q1 IQOS timing benefit reversing in Q4, device-comp normalization, and restock roll-off) and management said so explicitly. Underlying smoke-free momentum is unchanged and actually accelerated in Q2. Investors who see through the phasing get a compounder at a reset price.
Bear view: For a premium-multiple stock, reported growth rates are the multiple's oxygen. Even if the deceleration is optical, three quarters of choppier headline numbers (Q3 comp, Q4 combustible -3–4%, total volume possibly negative in H2) give the market reasons to keep the multiple in check and to punish any additional shipment wobble.
Our take: Both are right, which is why the stock is a Hold. The fundamentals justify seeing through the phasing; the multiple ensures the market won't fully do so until the H2 optics clear and Q4 confirms the ZYN step-up. Time, not thesis, is what stands between here and a higher rating.
Model & Valuation Framework
| Item | Our Estimate (Initiation) | Basis |
|---|---|---|
| FY25 Net Revenue Growth (organic) | +6.5–8% | Company guide maintained; H1 tracking ~+8.4% organic |
| FY25 Adjusted OI Growth (organic) | +11–12.5% | Raised guide floor; +330bp Q2 margin expansion |
| FY25 Adjusted Diluted EPS | $7.43–$7.56 (mid $7.50) | Company guide; +13–15% reported |
| FY25 Adjusted OI Margin | ~41–42% | H1 at 41.3%; smoke-free mix + cost program |
| FY26 Adjusted EPS (preliminary) | $8.40–$8.70 | ~12–14% growth off FY25 base; leverage + mix |
| Smoke-free % of net revenue (FY25E) | ~42–43% | Q2 at 41%; crossing 50% plausibly in 2026 |
| Dividend (annualized) | $5.40 (~3.3% yield) | $1.35 quarterly; progressive policy |
| Net debt / adj. EBITDA target | ~2.0x by end-2026 | Deleveraging-first; no 2025 buybacks |
Valuation: At the post-print price of $165.27 and an FY25 adjusted EPS midpoint of ~$7.50, PMI trades at ~22.0x forward earnings, with a ~3.3% dividend yield. That is a full multiple for a nicotine company (roughly 5–7 turns above where PMI traded before the smoke-free re-rating) but a reasonable one for a business compounding EPS in the low-teens with expanding margins and a self-funding dividend. On a forward FY26 EPS of ~$8.55, the stock trades at ~19x, which is where the value argument gets more interesting.
12-month price target framework: Base case ~$175–185 (roughly 22–23x our ~$8.00 blended NTM EPS, in line with the current multiple as EPS compounds), implying a mid-single-digit price return plus the ~3.3% yield: a total return roughly in line with our S&P 500 expectation, consistent with a Hold. Bull case ~$205–215 (24x on $8.75 if ZYN offtake sustains mid-30s%, IQOS holds double-digit IMS, and the multiple re-expands toward a staples-platform premium). Bear case ~$135–145 (17–18x if the ZYN growth premium unwinds, combustible declines accelerate, or a regulatory/FX shock compresses the multiple). The up-to-down skew from $165 is roughly balanced (~+22% bull / ~-15% bear), which is the definition of a Hold rather than an Outperform.
Thesis Scorecard: Initiating Coverage
This is our initiation of coverage on Philip Morris International. There is no prior standing thesis to grade; instead, we establish the pillars we will track each quarter. The Q2 2025 print is the baseline against which future quarters are scored.
| Thesis Point | Status (Q2 2025) | Notes |
|---|---|---|
| Bull #1: Smoke-free inflection re-rates the business | Confirmed / On Track | SFB 41% of revenue (+2.9pp), 42% of gross profit, >70% gross margin; the structural engine of the story |
| Bull #2: IQOS is a durable double-digit compounder | Confirmed | HTU adjusted IMS reaccelerated to +11.4%; Europe flavor-ban overhang clearing; 76% HnB share; Japan 31.7% |
| Bull #3: ZYN adds a second U.S. growth leg | On Track (optics noisy) | Offtake back to +26%/+36% June; capacity unconstrained; but shipments distorted by restock roll-off |
| Bull #4: Combustible resilience funds the transition | Confirmed | Pricing +7.2% drives +5% gross-profit growth despite -1.5% volume; Marlboro post-spin share high 10.7% |
| Bear #1: Valuation / crowded positioning caps upside | Active | ~22x forward after +50% YTD; the -8.4% reaction to a beat-and-raise is the market pricing perfection |
| Bear #2: ZYN demand-quality & shipment volatility | Contained | Restock below plan; first sequential shipment decline; Q3 destocking risk; resolves if offtake holds |
| Bear #3: H2 phasing + combustible acceleration | Contained | Q4 IQOS timing reversal, no device comp, combustible -3–4% H2; FX-quality of the raise |
| Bear #4: Regulatory (EU TED, FDA ILUMA, flavor bans) | Contained | EU excise revision a multi-year process; FDA ILUMA slipping toward 2026; monitor, not near-term P&L |
Overall: The bull case is confirmed on three of four pillars and on track on the fourth; the business is executing the best consumer-staples transformation in the market. The bear case is dominated by a single, entirely valuation-and-positioning point: the stock is priced for the perfection it did not quite deliver on the revenue line.
Action: Initiate at Hold. Own the transformation at the right price; the right price is not 22x after a +50% run into a beat-and-raise the market sold. We would upgrade to Outperform on (1) a further valuation reset that improves the entry, or (2) confirmation that ZYN offtake sustains mid-30s% and IQOS holds double-digit IMS through H2, resolving the demand-quality question. We would move toward Underperform only on evidence that ZYN offtake is rolling over or that combustible pricing power is breaking.
Bottom Line: A Great Business at a Fair Price
Philip Morris delivered an operationally excellent quarter: record revenue, a reaccelerating IQOS franchise, a ZYN offtake recovery, 330bp of adjusted-OI-margin expansion, and a guidance raise. The 8.4% sell-off was not a verdict on the business; it was a verdict on the price. A stock that had run 50% year-to-date and traded near record highs met a 1% revenue miss on its two most-watched growth lines and a currency-quality question on the raise, and the premium corrected.
We are initiating at Hold because both of those things are true at once: the transformation is real, best-in-class, and confirmed: and the valuation already reflects most of it. At ~22x forward earnings with a ~3.3% yield and low-teens EPS growth, the total-return algorithm is attractive but roughly market-like over the next twelve months, and the near-term setup carries pre-flagged phasing headwinds plus an unresolved ZYN shipment/offtake reconciliation. That is a Hold, not an Outperform.
The path to a higher rating is clear and specific. If the post-print reset extends and improves the entry, or if Q3–Q4 confirm that ZYN offtake holds mid-30s% and IQOS sustains double-digit IMS through the tougher comps, the demand-quality question resolves and the risk/reward turns asymmetric. We would upgrade at that point. For now, we want to own this business, and we want to own it a little cheaper or with one more quarter of confirmation.